J2H 1701
Alternative Names: J2H-1701Latest Information Update: 01 Apr 2021
At a glance
- Originator J2H Biotech
- Class Antivirals; Hepatoprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hepatitis C
Most Recent Events
- 23 Mar 2021 Preclinical trials in Hepatitis C in South Korea (unspecified route) prior to March 2021 (J2H Biotech pipeline, March 2021)